Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
80Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-161.15M | $-3.66 |
| 2024 | $0.00 | $-77.58M | $-1.87 |
| 2023 | $0.00 | $-55.71M | $-1.34 |
| 2022 | $0.00 | $-30.02M | $-0.72 |
Social Signal Score
Earnings
Fri, Sep 18(in 5 weeks)
Consensus estimate $-1.33 per share
Typical surprise -23.2% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-1.32 vs $-1.35beat
- Fri, May 15$-1.34 vs $-1.05miss
- Thu, Dec 4$-37.18 vs $-1.72miss
- Fri, Aug 22$-1.14 vs $-0.96miss
Estimates and results for MPLT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
MPLThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsglobenewswire.com·2d ago·Negative
…ight Therapeutics Announces $150 Million Private Placement Financing SAN FRANCISCO and BOSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the “PIPE…
View source ↗